96413

Chemotherapy administration, intravenous infusion technique; up to 1 hour

CPT code 96413 describes the professional and technical services associated with the administration of chemotherapy drugs via an intravenous infusion technique, lasting up to one hour. This code is used for the initial hour of a single, continuous intravenous infusion of antineoplastic agents. Chemotherapy administration is a critical component in the treatment of various cancers and certain non-malignant conditions. The process involves meticulous preparation, precise drug delivery, and vigilant patient monitoring. Prior to administration, the patient's medical history, current status, and laboratory values are reviewed to ensure suitability for treatment. The chemotherapy agent, often a cytotoxic drug, is prepared according to strict sterile protocols, often requiring specialized training and equipment due to its hazardous nature. Access to the venous system is typically achieved through a peripheral IV line, a central venous catheter (e.g., PICC line, implanted port), or another suitable vascular access device. During the infusion, healthcare professionals closely monitor the patient for adverse reactions, including hypersensitivity, extravasation, and other acute toxicities. Vital signs are continuously assessed, and supportive medications (e.g., antiemetics, antihistamines) may be co-administered. The duration of the infusion is a key factor in coding, with this code specifically covering the first 60 minutes of the continuous infusion. The goal of chemotherapy is to destroy cancer cells, slow their growth, or palliate symptoms, making precise and safe administration paramount to achieving therapeutic outcomes while minimizing risks to the patient.

Clinical Indications

  • Breast cancer (e.g., adjuvant, neoadjuvant, metastatic)
  • Colorectal cancer (e.g., adjuvant, metastatic)
  • Lung cancer (e.g., non-small cell, small cell)
  • Leukemias (e.g., acute myeloid leukemia, acute lymphoblastic leukemia)
  • Lymphomas (e.g., Hodgkin lymphoma, non-Hodgkin lymphoma)
  • Ovarian cancer
  • Pancreatic cancer
  • Gastric cancer
  • Head and neck cancers
  • Sarcomas
  • Germ cell tumors
  • Multiple myeloma
  • Autoimmune disorders (e.g., severe rheumatoid arthritis, lupus - in some cases where immunosuppressive chemotherapy agents are used off-label)
  • Solid organ transplant rejection prevention (certain immunosuppressive protocols)
  • Other solid tumors and hematologic malignancies requiring systemic chemotherapy

Procedure Steps

  1. Patient Identification and Verification: Confirm patient identity, treatment plan, and chemotherapy regimen.
  2. Pre-Treatment Assessment: Review patient's current symptoms, vital signs, lab results (e.g., CBC, metabolic panel, liver/kidney function tests), and assess eligibility for treatment.
  3. Informed Consent: Ensure the patient has provided informed consent for the chemotherapy treatment.
  4. Vascular Access: Establish or verify patency of appropriate intravenous access (e.g., peripheral IV, central venous catheter, implanted port). Flush line and check for blood return.
  5. Pre-medication Administration: Administer pre-medications (e.g., antiemetics, antihistamines, corticosteroids) as prescribed to prevent or mitigate side effects. These are typically administered via separate infusion or push.
  6. Chemotherapy Preparation: Trained personnel (e.g., pharmacist, nurse) prepare the specific chemotherapy drug(s) in a sterile environment, calculating doses precisely based on patient parameters (e.g., body surface area, weight).
  7. Initiation of Infusion: Connect the prepared chemotherapy drug to the patient's intravenous access device using an infusion pump for controlled delivery.
  8. Monitoring during Infusion: Continuously monitor the patient for adverse reactions such as hypersensitivity reactions, extravasation, anaphylaxis, changes in vital signs, pain, or discomfort.
  9. Documentation: Record start time, drug name, dose, infusion rate, patient response, and any interventions.
  10. Post-Infusion Care: Once the infusion is complete (within the 60-minute timeframe for 96413), flush the intravenous line, disconnect the infusion, and secure or remove the access device as appropriate. Provide patient education on potential delayed side effects and when to seek medical attention.

Coding Guidelines

  • Initial Hour: Code 96413 is used for the initial hour (or any part thereof) of a single continuous intravenous infusion of chemotherapy.
  • Additional Hours: For infusions lasting longer than one hour, use CPT code 96415 for each additional hour (or major fraction thereof, typically defined as greater than 31 minutes beyond the initial hour/subsequent hour). For example, a 90-minute infusion would be coded 96413 once. A 120-minute infusion would be coded 96413 and 96415.
  • Concurrent Infusions: If multiple distinct chemotherapy infusions are administered concurrently, 96413 can be reported once for the initial hour of each distinct chemotherapy drug administered by infusion. However, this is complex and often requires modifier 59 or other specific payer rules. Generally, for a single patient encounter, only one 'initial' code (96413, 96409, 96416, etc.) from the chemotherapy administration series is reported, based on the primary infusion. Check NCCI edits carefully.
  • Sequential Infusions: If chemotherapy infusions are administered sequentially (one after another) and each infusion lasts less than an hour, typically only one initial chemotherapy infusion code is reported, and subsequent infusions might be reported with 96417 (for non-chemo infusions) or bundled. Always verify payer specific guidelines.
  • Hydration/Other IV Infusions: If hydration (96360-96361) or other therapeutic/prophylactic/diagnostic injections/infusions (96365-96379) are administered concomitantly with chemotherapy, they may be separately reported if they meet specific criteria and are not considered routine or integral to the chemotherapy administration. For example, pre-chemo hydration or antiemetic infusions may be separately billable if they represent distinct therapeutic interventions and meet time requirements.
  • Push vs. Infusion: CPT 96413 is specifically for infusion technique. Chemotherapy administered via IV push is coded with 96409.
  • Central Line Maintenance: Routine flushing and maintenance of central lines are typically bundled into the administration code. Insertion of a central line is separately reportable.
  • Extravasation Management: If extravasation occurs and requires significant intervention beyond simply stopping the infusion, specific codes for drug removal or management might apply, but the initial administration code would still be reported for the attempt.

Associated ICD-10 Codes